CN117425656A - 作为抗癌剂的嘌呤衍生物 - Google Patents

作为抗癌剂的嘌呤衍生物 Download PDF

Info

Publication number
CN117425656A
CN117425656A CN202280035481.2A CN202280035481A CN117425656A CN 117425656 A CN117425656 A CN 117425656A CN 202280035481 A CN202280035481 A CN 202280035481A CN 117425656 A CN117425656 A CN 117425656A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
compound
aryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280035481.2A
Other languages
English (en)
Chinese (zh)
Inventor
S·斯罗纳
D·琼森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Tango Pharmaceutical Co ltd
Original Assignee
Medivir AB
Tango Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir AB, Tango Pharmaceutical Co ltd filed Critical Medivir AB
Publication of CN117425656A publication Critical patent/CN117425656A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280035481.2A 2021-03-17 2022-03-17 作为抗癌剂的嘌呤衍生物 Pending CN117425656A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162460P 2021-03-17 2021-03-17
US63/162,460 2021-03-17
PCT/US2022/020700 WO2022197892A1 (en) 2021-03-17 2022-03-17 Purine derivatives as anticancer agents

Publications (1)

Publication Number Publication Date
CN117425656A true CN117425656A (zh) 2024-01-19

Family

ID=81327909

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280035481.2A Pending CN117425656A (zh) 2021-03-17 2022-03-17 作为抗癌剂的嘌呤衍生物

Country Status (11)

Country Link
US (1) US20240059689A1 (https=)
EP (1) EP4308566A1 (https=)
JP (1) JP2024511996A (https=)
KR (1) KR20240006509A (https=)
CN (1) CN117425656A (https=)
AU (1) AU2022238886A1 (https=)
BR (1) BR112023018799A2 (https=)
CA (1) CA3212292A1 (https=)
IL (1) IL305991A (https=)
MX (1) MX2023010909A (https=)
WO (1) WO2022197892A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119751316A (zh) * 2024-12-20 2025-04-04 江南大学 一种1-苯基三氟甲基n-（氟磺酰基）氨基甲酸酯化合物的制备方法
WO2025256544A1 (zh) * 2024-06-11 2025-12-18 福建盛迪医药有限公司 一种1-氨烷基修饰的呋喃核糖衍生物的制备方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312642A (en) 2021-11-12 2024-07-01 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
EP4430049A4 (en) * 2021-11-12 2025-12-17 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof
TW202509030A (zh) 2023-05-08 2025-03-01 美商譚格醫療公司 化合物及使用方法
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
CN117024253A (zh) * 2023-08-14 2023-11-10 江西阿尔法高科药业有限公司 一种药用级麝香草酚特定杂质的制备方法
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
TW202539659A (zh) 2024-01-10 2025-10-16 美商維瑞斯治療股份有限公司 Ｄｎａ損傷修復途徑的新穎抑制劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
JP2011236198A (ja) * 2010-04-13 2011-11-24 Daiichi Sankyo Co Ltd モルホリノプリン誘導体
CN108473495B (zh) * 2015-11-20 2022-04-12 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
US11485736B2 (en) * 2018-12-20 2022-11-01 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025256544A1 (zh) * 2024-06-11 2025-12-18 福建盛迪医药有限公司 一种1-氨烷基修饰的呋喃核糖衍生物的制备方法
CN119751316A (zh) * 2024-12-20 2025-04-04 江南大学 一种1-苯基三氟甲基n-（氟磺酰基）氨基甲酸酯化合物的制备方法

Also Published As

Publication number Publication date
KR20240006509A (ko) 2024-01-15
IL305991A (en) 2023-11-01
MX2023010909A (es) 2024-02-13
JP2024511996A (ja) 2024-03-18
AU2022238886A1 (en) 2023-09-14
WO2022197892A1 (en) 2022-09-22
EP4308566A1 (en) 2024-01-24
BR112023018799A2 (pt) 2023-12-12
CA3212292A1 (en) 2022-09-22
US20240059689A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
CN117425656A (zh) 作为抗癌剂的嘌呤衍生物
JP7833597B2 (ja) Ｃｄｋ２阻害剤としての二環式アミン
US12312331B2 (en) Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US10253044B2 (en) 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors
CN110177791B (zh) 氨基-三唑并吡啶化合物及其在治疗癌症中的用途
US20240182481A1 (en) Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
CN114040764A (zh) 细胞周期素依赖性激酶2生物标记物及其用途
WO2021086879A1 (en) Compounds and methods of use
US11986471B2 (en) Compounds and methods of use
JP2025503970A (ja) 化合物及び使用方法
WO2024233605A1 (en) Compounds and their use against cancer
US20250171432A1 (en) Compounds and methods of use
CN120379983A (zh) Polo样激酶4抑制剂
WO2024233665A1 (en) Compounds and their use against cancer
CN117120447A (zh) 环状化合物和其使用方法
CN118715207A (zh) 化合物和使用方法
TW202300150A (zh) 環狀化合物及其使用方法
HK1254965B (zh) 新化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination